Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants

Mian, AA, Haberbosch, I., Khamaisie, H., Agbarya, A., Pietsch, L., Eshel, E., Dally, N., Claudia Chiriches, C., Ottmann, O., Hantschel, O., Biondi, R., Ruthardt, M., and Mahajna, J.